title: Stroke and anti-VEGF therapy.
authors.forename: Takashi
authors.initials: T
authors.lastname: Ueta
authors.forename: Harushi
authors.initials: H
authors.lastname: Mori
authors.forename: Akira
authors.initials: A
authors.lastname: Kunimatsu
authors.forename: Takuhiro
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Tamaki
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Yanagi
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D000068258:Bevacizumab; D005122:Exudates and Transudates; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D008297:Male; D000069579:Ranibizumab; D012307:Risk Factors; D020521:Stroke / Q000139:chemically induced* / Q000175:diagnosis; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab